<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Naratriptan: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Naratriptan: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Naratriptan: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="10893" href="/d/html/10893.html" rel="external">see "Naratriptan: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F199952"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Amerge [DSC]</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52867647"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Amerge [DSC];</li>
<li>SANDOZ Naratriptan;</li>
<li>TEVA-Naratriptan</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F199986"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antimigraine Agent;</li>
<li>
                        Serotonin 5-HT<sub>1B, 1D</sub> Receptor Agonist</li></ul></div>
<div class="block doa drugH1Div" id="F199957"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Do <b>not</b> use within 24 hours of an ergotamine preparation or a different triptan. Limit use to &lt;10 days per month to avoid medication-overuse headache (AHS [Ailani 2021]).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3b95dc6b-a5ab-47db-a337-1fb0b6724097">Menstrual migraine prevention</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Menstrual migraine prevention (off-label use):</b>
<b>Oral:</b> 1 mg twice daily beginning 2 to 3 days prior to expected onset of symptoms; continue for a total of 5 to 6 days (Mannix 2007; Newman 2001).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d36d256f-8d0c-47cc-acaf-2f0f3747bed4">Migraine, moderate to severe, acute treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Migraine, moderate to severe, acute treatment:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Administration early in the course of a migraine attack, at the first sign of pain, may improve response to treatment. When attack is complicated by severe nausea or vomiting, a nonoral medication may be more effective (AHS [Ailani 2021]).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 2.5 mg as a single dose; if symptoms persist or return, may repeat dose after ≥4 hours. Maximum: 2.5 mg/dose; 5 mg per 24 hours (Mathew 1997; manufacturer’s labeling).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991566"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild to moderate renal impairment: Initial: 1 mg; maximum dose: 2.5 mg per 24 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Severe renal impairment (CrCl &lt;15 mL/minute): Use is contraindicated.</p></div>
<div class="block doha drugH1Div" id="F50988621"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild to moderate hepatic impairment (Child-Pugh grade A or B): Initial: 1 mg; maximum dose: 2.5 mg per 24 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Severe hepatic impairment (Child-Pugh grade C): Use is contraindicated.</p></div>
<div class="block doe drugH1Div" id="F199958"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing. Dosing should generally start at the lower end of the dosing range due to possible increased incidence of hepatic, renal, and cardiac impairment.</p></div>
<div class="block adr drugH1Div" id="F199928"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">1% to 10%: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Central nervous system: Pain (4%), fatigue (2%), dizziness (1% to 2%), drowsiness (1% to 2%), paresthesia (1% to 2%), hot and cold flashes (1%), sensation of pressure (1%; chest/neck/throat/jaw), vertigo (1%)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Gastrointestinal: Nausea (4% to 5%), vomiting (1%), xerostomia (1%)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Neuromuscular &amp; skeletal: Neck pain (2%)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ophthalmic: Photophobia (1%)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Respiratory: Constriction of the pharynx (2%), ENT infection (1%)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">&lt;1%, postmarketing, and/or case reports (limited to important or life-threatening): Abnormal bilirubin levels, abnormal hepatic function tests, anaphylactoid reaction, anaphylaxis, anemia, angina pectoris, angioedema, bradycardia, cerebral infarction, colonic ischemia, coronary artery vasospasm, depression, dyspnea, ECG changes (atrial fibrillation, atrial flutter, premature ventricular contractions, PR prolongation, or QT<sub>c</sub> prolongation), glycosuria, hallucination, heart murmur, hypercholesterolemia, hyperglycemia, hyperlipidemia, hypersensitivity reaction (some cases severe, including circulatory collapse), hypertension, hypotension, hypothyroidism, ischemic heart disease, ketonuria, myocardial infarction, palpitations, panic, seizure, serotonin syndrome, skin rash, subarachnoid hemorrhage, subconjunctival hemorrhage, syncope, thrombocytopenia, transient ischemic attacks, ventricular fibrillation, ventricular tachycardia</p></div>
<div class="block coi drugH1Div" id="F199939"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Ischemic coronary artery disease (CAD) (angina pectoris, history of myocardial infarction [MI], or documented silent ischemia); coronary artery vasospasm, including Prinzmetal's angina; Wolff-Parkinson-White syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders; history of stroke, transient ischemic attack (TIA), or history of hemiplegic migraine or migraine with brainstem aura; peripheral vascular disease; ischemic bowel disease; uncontrolled hypertension; recent use (within 24 hours) of another 5-HT<sub>1</sub> agonist, ergotamine-containing medication, or ergot-type medication (eg, dihydroergotamine or methysergide); severe renal impairment (CrCl &lt;15 mL/minute) or severe hepatic impairment; hypersensitivity to naratriptan or any component of the formulation</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Severe hypertension, cardiac arrhythmias (especially tachycardias); valvular heart disease, significant underlying cardiovascular disease (eg, congenital heart disease, atherosclerotic disease); management of ophthalmoplegic migraine</p></div>
<div class="block war drugH1Div" id="F199925"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Anaphylactic reactions: Anaphylaxis and hypersensitivity reactions (including angioedema) have occurred; may be life-threatening or fatal. Use is contraindicated in patients with known hypersensitivity to naratriptan.</p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiac events: Coronary artery vasospasm, transient ischemia, myocardial infarction, ventricular tachycardia/fibrillation, cardiac arrest, and death have been reported with 5-HT<sub>1</sub> agonist administration; some events have occurred within a few hours of administration. Discontinue if these events occur. Patients who experience sensations of chest pain/pressure/tightness or symptoms suggestive of angina following dosing should be evaluated for coronary artery disease (CAD) or Prinzmetal's angina before receiving additional doses; if dosing is resumed and similar symptoms recur, monitor with ECG. Use is contraindicated in patients with ischemic or vasospastic CAD and Wolff-Parkinson-White syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders.</p>
<p style="text-indent:-2em;margin-left:4em;">• Cerebrovascular events: Cerebral/subarachnoid hemorrhage and stroke (some fatal) have been reported with 5-HT<sub>1</sub> agonist administration. Use is contraindicated in patients with a history of stroke or transient ischemic attack.</p>
<p style="text-indent:-2em;margin-left:4em;">• CNS depression: May cause CNS depression, such as dizziness, weakness, or drowsiness, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).</p>
<p style="text-indent:-2em;margin-left:4em;">• Elevated blood pressure: Significant elevation in blood pressure, including hypertensive crisis with acute impairment of organ systems, has been reported on rare occasions in patients with and without a history of hypertension. Monitor blood pressure; use is contraindicated in patients with uncontrolled hypertension.</p>
<p style="text-indent:-2em;margin-left:4em;">• Headaches: Acute migraine agents (eg, triptans, opioids, ergotamine, or a combination of the agents) used for 10 or more days per month may lead to worsening of headaches (medication overuse headache); withdrawal treatment may be necessary in the setting of overuse.</p>
<p style="text-indent:-2em;margin-left:4em;">• Vasospasm-related events: Peripheral vascular ischemia and colonic ischemia, gastrointestinal vascular ischemia and infarction, splenic infarction, and Raynaud syndrome have been reported with 5-HT<sub>1</sub> agonist administration.</p>
<p style="text-indent:-2em;margin-left:4em;">• Visual effects: Partial vision loss and blindness (transient and permanent) have been reported with use of 5-HT<sub>1</sub> agonists; a causal relationship between these events and 5-HT<sub>1</sub> agonist administration has not been clearly determined.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Coronary artery disease: Should not be given to patients who have risk factors for CAD (eg, hypertension, hypercholesterolemia, smoker, obesity, diabetes, strong family history of CAD, menopause, male &gt;40 years of age) without adequate cardiac evaluation. Use is contraindicated if there is evidence of CAD or coronary artery vasospasm. Patients with suspected CAD should have cardiovascular evaluation to rule out CAD before considering use; if cardiovascular evaluation is “satisfactory,” first dose should be given in the health care provider's office (consider ECG monitoring). Periodic evaluation of cardiovascular status should be done in all patients.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use is contraindicated in patients with severe hepatic impairment (Child-Pugh grade C).</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use is contraindicated in patients with severe renal impairment (CrCl &lt;15 mL/minute).</p>
<p style="text-indent:-4em;margin-left:4em;">
<b>
<i>Concurrent drug therapy issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Serotonin syndrome: Symptoms of agitation, confusion, hallucinations, hyper-reflexia, myoclonus, shivering, and tachycardia may occur with concomitant proserotonergic drugs (ie, SSRIs/SNRIs or triptans) or agents which reduce naratriptan's metabolism. Concurrent use of serotonin precursors (eg, tryptophan) is not recommended. If concomitant administration with SSRIs is warranted, monitor closely, especially at initiation and with dose increases. Discontinue naratriptan if serotonin syndrome is suspected.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Blood pressure increases may be more pronounced in the elderly.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Only indicated for the acute treatment of migraine; not indicated for migraine prophylaxis, or for the treatment of cluster headache, hemiplegic, or basilar migraine. If a patient does not respond to the first dose, the diagnosis of migraine should be reconsidered; rule out underlying neurologic disease in patients with atypical headache and in patients with no prior history of migraine.</p></div>
<div class="block foc drugH1Div" id="F199933"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Amerge: 1 mg [DSC], 2.5 mg [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1 mg, 2.5 mg</p></div>
<div class="block geq drugH1Div" id="F199921"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F199940"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Naratriptan HCl Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 mg (per each): $25.00 - $29.49</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2.5 mg (per each): $25.00 - $29.49</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867648"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Amerge: 1 mg [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Amerge: 2.5 mg [DSC] [contains fd&amp;c blue #2 (indigo carm) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1 mg, 2.5 mg</p></div>
<div class="block adm drugH1Div" id="F803174"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral:</b> Administer orally as soon as symptoms appear; may take with or without food. Do <b>not</b> crush or chew tablet; swallow whole with water.</p></div>
<div class="block use drugH1Div" id="F199936"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Migraine, moderate to severe, acute treatment:</b> Acute treatment of migraine attacks with or without aura in adults.</p></div>
<div class="block off-label drugH1Div" id="F25731083"><span class="drugH1">Use: Off-Label: Adult</span><p>Menstrual migraine prevention</p></div>
<div class="block mst drugH1Div" id="F199993"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Amerge may be confused with Altace, Amaryl</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299745"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F199929"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Bromocriptine: May enhance the adverse/toxic effect of Serotonin 5-HT1D Receptor Agonists (Triptans). Management: Consider alternatives to this combination when possible. If combined, monitor for increased bromocriptine and triptan toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Droxidopa: Serotonin 5-HT1D Receptor Agonists (Triptans) may enhance the hypertensive effect of Droxidopa. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates): Serotonin 5-HT1D Receptor Agonists (Triptans) may enhance the vasoconstricting effect of Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Monoamine Oxidase Inhibitors: Serotonin 5-HT1D Receptor Agonists (Triptans) may enhance the serotonergic effect of Monoamine Oxidase Inhibitors. This could result in serotonin syndrome. Monoamine Oxidase Inhibitors may increase the serum concentration of Serotonin 5-HT1D Receptor Agonists (Triptans). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonergic Agents (High Risk): Serotonin 5-HT1D Receptor Agonists (Triptans) may enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome.  Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonin 5-HT1D Receptor Agonists (Triptans): May enhance the vasoconstricting effect of other Serotonin 5-HT1D Receptor Agonists (Triptans).<i> Risk X: Avoid combination</i></p></div>
<div class="block pri drugH1Div" id="F199941"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Pregnancy outcome data for naratriptan is available from a pregnancy registry sponsored by GlaxoSmithKline. As of September 2012, data were available for 57 infants/fetuses exposed to naratriptan (52 during the first trimester), and seven exposed to both naratriptan and sumatriptan. Following naratriptan exposure, there was one infant born with a birth defect; this infant was also exposed to sumatriptan during the first trimester of pregnancy. The pregnancy registry was closed to enrollment in January 2012 (Ephross 2014). Additional data related to the use of naratriptan in pregnancy is limited in comparison to other 5-HT<sub>1B/1D</sub> agonists (triptans) (Källén 2011; Nezvalová-Henriksen 2010; Nezvalová-Henriksen 2012; Nezvalová-Henriksen 2013; Spielmann 2018; Yusuf 2018).</p>
<p style="text-indent:0em;margin-top:2em;">Triptans relieve migraine pain by selectively binding to serotonin receptors, resulting in vasoconstriction of cranial arteries. Although the effects on uterine blood flow have not been evaluated, one case report suggests excessive use of a triptan may cause placental hypoperfusion (ACOG 2022; Viard 2021).</p>
<p style="text-indent:0em;margin-top:2em;">Treatment for migraine headaches in pregnant patients should be individualized (AHS [Ailani 2021]). Triptans are not the preferred initial treatment for acute migraine headache in pregnant patients (ACOG 2022). Until additional data are available, naratriptan is not the preferred triptan when first-line therapy is ineffective. Triptans should be avoided in pregnant patients with cardiac disease or hypertension (ACOG 2022; CHS [Worthington 2013]).</p></div>
<div class="block brc drugH1Div" id="F20616472"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Naratriptan is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Data related to the presence of 5-HT<sub>1B/1D</sub> agonists (triptans) in breast milk is available from a study of 19 lactating women (6 weeks to 30 months postpartum) treated for migraine headaches. During the study, infants were fed previously expressed breast milk. Breast milk was sampled prior to and at intervals up to 24 hours after the dose in one patient taking naratriptan 2.5 mg. Using the average breast milk concentration observed, authors of the study calculated the estimated exposure of naratriptan to the breastfed infant to be 1.9 mcg/kg/day, providing a relative infant dose (RID) of 5% based on the weight adjusted maternal dose. Using the maximum breast milk concentration, the RID of naratriptan was calculated to be 9%. A large interindividual variability among breast milk concentrations was found with all the triptans in the study, even when considering dose and dosage form (Amundsen 2021). In general, breastfeeding is considered acceptable when the RID is &lt;10% (Anderson 2016; Ito 2000).</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother. Treatment for migraine headaches in lactating patients should be individualized (AHS [Ailani 2021]). Withholding breastfeeding for 24 hours after the maternal dose will minimize infant exposure via breast milk. The decision to withhold breastfeeding following a dose of naratriptan should be part of a shared decision-making process (ACOG 2022).</p></div>
<div class="block mop drugH1Div" id="F22790359"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Headache severity, blood pressure, signs/symptoms suggestive of angina; perform a cardiovascular evaluation in triptan-naïve patients who have multiple cardiovascular risk factors (eg, increased age, diabetes, hypertension, smoking, obesity, strong family history of CAD), monitor ECG with first dose in patients with multiple cardiovascular risk factors who have a negative cardiovascular evaluation and consider periodic cardiovascular evaluation in such patients if they are intermittent long-term users; signs/symptoms of serotonin syndrome and hypersensitivity reactions.</p></div>
<div class="block pha drugH1Div" id="F199924"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Selective agonist for serotonin (5-HT<sub>1B</sub> and 5-HT<sub>1D</sub> receptors) in cranial arteries; causes vasoconstriction and reduces sterile inflammation associated with antidromic neuronal transmission correlating with relief of migraine</p></div>
<div class="block phk drugH1Div" id="F199938"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Onset of action: ~1 to 2 hours (Bomhof 1999; Tfelt-Hansen 2000) </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Absorption: Well absorbed</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Distribution: V<sub>dss</sub>: 170 L</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Protein binding, plasma: 28% to 31% </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: Hepatic via CYP </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Bioavailability: ~70%</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: 6 hours; Increased in renal impairment (moderate impairment; mean: 11 hours; range: 7 to 20 hours); Increased in hepatic impairment (moderate impairment: 8 to 16 hours)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Time to peak: 2 to 3 hours </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Urine (50% of total dose as unchanged drug; 30% of total dose as metabolites)</p></div>
<div class="block phksp drugH1Div" id="F51154883"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Naratriptan clearance is reduced 50% with moderate impairment (CrCl 18 to 39 mL/minute); mean C<sub>max</sub> increased ~40%.</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: Naratriptan clearance is decreased 30% in patients with moderate impairment (Child-Pugh class A or B).</p>
<p style="text-indent:-2em;margin-left:2em;">Older adult: Clearance is decreased ~26% in healthy elderly subjects (65 to 77 years) compared with younger patients.</p>
<p style="text-indent:-2em;margin-left:2em;">Sex: C<sub>max</sub> is 50% higher in women.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F199942"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Naramig</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Naramig</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Antimigrin | Naramig</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Naramig</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Naramig | Naratriptan sandoz</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Naramig</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Cloridrato de naratriptana | Naramig | Naranety | Naratano | Naratrin | Narcef</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Naramig</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Bagomigral | Migtal | Miragran | Naramig | Nartan | Zomigren</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Naramig</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Naramig</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Contramig | Formigran | Naradex | NaraHennig bei Migraene | Naramig | Naratriptan 1A pharma | Naratriptan actavis | Naratriptan AL | Naratriptan beta | Naratriptan ct | Naratriptan heumann | Naratriptan hexal | Naratriptan hormosan | Naratriptan juta | Naratriptan neuraxpharm | Naratriptan ratiopharm | Naratriptan stada</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Naramig</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Naramig</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Naramig</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Naramig | Naredrix</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Naramig | Naratriptan Kern</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Naramig | Naratriptan orifarm</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Naramig | Naratriptan | Naratriptan Arrow | Naratriptan biogaran | Naratriptan EG | Naratriptan mylan | Naratriptan sandoz | Naratriptan Teva | Naratriptan Zydus</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Naramig | Naratriptan | Naratriptan Kent</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Naramig</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Naramig</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Naramig</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Naramerg | Naraverg</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Naramig</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Naramig</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Amerge</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Naramig</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Naramig</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Naramig</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Naramig</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Naramig</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Naramig | Naratriptan actavis | Naratriptan cf | Naratriptan mylan | Naratriptan pch | Naratriptan sandoz</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Naramig | Naratriptan orifarm</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Naramig</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Naramig</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Amerge | Naratriptan</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Naramig</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Naramig</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Naramig</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Naramig | Naratriptan orifarm</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Naramig</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Naramig</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Naramig</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Naramig</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Naramig</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Naramig</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Naramig</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-34160823">
<a name="34160823"></a>Ailani J, Burch RC, Robbins MS; Board of Directors of the American Headache Society. The American Headache Society consensus statement: update on integrating new migraine treatments into clinical practice. <i>Headache</i>. 2021;61(7):1021-1039. doi:10.1111/head.14153<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naratriptan-drug-information/abstract-text/34160823/pubmed" id="34160823" target="_blank">34160823</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Amerge (naratriptan) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; October 2020.</div>
</li>
<li>
<div class="reference">
                  Amerge (naratriptan) [product monograph]. Mississauga, Ontario, Canada: GlaxoSmithKline Inc; November 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35576364">
<a name="35576364"></a>American College of Obstetricians and Gynecologists (ACOG). Headaches in pregnancy and postpartum: ACOG clinical practice guideline no. 3. <i>Obstet Gynecol</i>. 2022;139(5):944-972. doi:10.1097/AOG.0000000000004766<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naratriptan-drug-information/abstract-text/35576364/pubmed" id="35576364" target="_blank">35576364</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33730376">
<a name="33730376"></a>Amundsen S, Nordeng H, Fuskevåg OM, Nordmo E, Sager G, Spigset O. Transfer of triptans into human breast milk and estimation of infant drug exposure through breastfeeding. <i>Basic Clin Pharmacol Toxicol</i>. 2021;128(6):795-804. doi:10.1111/bcpt.13579<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naratriptan-drug-information/abstract-text/33730376/pubmed" id="33730376" target="_blank">33730376</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27060684">
<a name="27060684"></a>Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52. doi:10.1002/cpt.377<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naratriptan-drug-information/abstract-text/27060684/pubmed" id="27060684" target="_blank">27060684</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10529545">
<a name="10529545"></a>Bomhof MK, Paz J, Legg N, et al, “Comparison of Rizatriptan 10 mg vs Naratriptan 2.5 mg in Migraine,” <i>Eur Neurol</i> 1999, 42(3):173-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naratriptan-drug-information/abstract-text/10529545/pubmed" id="10529545" target="_blank">10529545</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15784664">
<a name="15784664"></a>Boyer EW and Shannon M, “The Serotonin Syndrome,” <i>N Engl J Med</i>, 2005, 352:1112-20.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naratriptan-drug-information/abstract-text/15784664/pubmed" id="15784664" target="_blank">15784664</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24805878">
<a name="24805878"></a>Ephross SA, Sinclair SM. Final results from the 16-year sumatriptan, naratriptan, and treximet pregnancy registry. <i>Headache</i>. 2014;54(7):1158-1172. doi:10.1111/head.12375<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naratriptan-drug-information/abstract-text/24805878/pubmed" id="24805878" target="_blank">24805878</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10891521">
<a name="10891521"></a>Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126. doi:10.1056/NEJM20000713343020<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naratriptan-drug-information/abstract-text/10891521/pubmed" id="10891521" target="_blank">10891521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21751829">
<a name="21751829"></a>Källén B, Nilsson E, and Otterblad Olausson P, "Delivery Outcome After Maternal Use of Drugs for Migraine: A Register Study in Sweden," <i>Drug Saf</i>, 2011, 34(8):691-703.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naratriptan-drug-information/abstract-text/21751829/pubmed" id="21751829" target="_blank">21751829</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17635595">
<a name="17635595"></a>Mannix LK, Savani N, Landy S, et al. Efficacy and tolerability of naratriptan for short-term prevention of menstrually related migraine: data from two randomized, double-blind, placebo-controlled studies. <i>Headache</i>. 2007;47(7):1037-1049.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naratriptan-drug-information/abstract-text/17635595/pubmed" id="17635595" target="_blank">17635595</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9409334">
<a name="9409334"></a>Mathew NT, Asgharnejad M, Peykamian M, Laurenza A. Naratriptan is effective and well tolerated in the acute treatment of migraine. Results of a double-blind, placebo-controlled, crossover study. The Naratriptan S2WA3003 Study Group. <i>Neurology</i>. 1997;49(6):1485-1490. doi:10.1212/wnl.49.6.1485<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naratriptan-drug-information/abstract-text/9409334/pubmed" id="9409334" target="_blank">9409334</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11264684">
<a name="11264684"></a>Newman L, Mannix LK, Landy S, et al. Naratriptan as short-term prophylaxis of menstrually associated migraine: a randomized, double-blind, placebo-controlled study. <i>Headache</i>. 2001;41(3):248-256.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naratriptan-drug-information/abstract-text/11264684/pubmed" id="11264684" target="_blank">11264684</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22946832">
<a name="22946832"></a>Nezvalová-Henriksen K, Spigset O, and Nordeng HM, "Errata in 'Triptan Exposure During Pregnancy and the Risk of Major Congenital Malformations and Adverse Pregnancy Outcomes: Results From the Norwegian Mother and Child Cohort Study,'" <i>Headache</i>, 2012, 52(8):1319-20.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naratriptan-drug-information/abstract-text/22946832/pubmed" id="22946832" target="_blank">22946832</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20132339">
<a name="20132339"></a>Nezvalová-Henriksen K, Spigset O, and Nordeng H, "Triptan Exposure During Pregnancy and the Risk of Major Congenital Malformations and Adverse Pregnancy Outcomes: Results From the Norwegian Mother and Child Cohort Study," <i>Headache</i>, 2010, 50(4):563-75.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naratriptan-drug-information/abstract-text/20132339/pubmed" id="20132339" target="_blank">20132339</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23884894">
<a name="23884894"></a>Nezvalová-Henriksen K, Spigset O, Nordeng H. Triptan safety during pregnancy: a Norwegian population registry study. <i>Eur J Epidemiol</i>. 2013;28(9):759-769. doi:10.1007/s10654-013-9831-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naratriptan-drug-information/abstract-text/23884894/pubmed" id="23884894" target="_blank">23884894</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22529202">
<a name="22529202"></a>Silberstein SD, Holland S, Freitag F, Dodick DW, Argoff C, Ashman E; Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. <i>Neurology</i>. 2012;78(17):1337-1345. doi: 10.1212/WNL.0b013e3182535d20.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naratriptan-drug-information/abstract-text/22529202/pubmed" id="22529202" target="_blank">22529202</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28758416">
<a name="28758416"></a>Spielmann K, Kayser A, Beck E, Meister R, Schaefer C. Pregnancy outcome after anti-migraine triptan use: a prospective observational cohort study. <i>Cephalalgia</i>. 2018;38(6):1081-1092. doi:10.1177/0333102417724152<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naratriptan-drug-information/abstract-text/28758416/pubmed" id="28758416" target="_blank">28758416</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11152011">
<a name="11152011"></a>Tfelt-Hansen P, de Vries P, Saxena PR, “Triptans in Migraine: A Comparative Review of Pharmacology, Pharmacokinetics and Efficacy,” <i>Drugs</i>, 2000, 60(6):1259-87.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naratriptan-drug-information/abstract-text/11152011/pubmed" id="11152011" target="_blank">11152011</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32886179">
<a name="32886179"></a>Viard D, Gérard A, Tahiri J, Tieulié N, Van Obberghen E, Drici MD. Triptan overuse during pregnancy: a possible cause of placental hypoperfusion. <i>Eur J Clin Pharmacol</i>. 2021;77(2):269-270. doi:10.1007/s00228-020-02991-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naratriptan-drug-information/abstract-text/32886179/pubmed" id="32886179" target="_blank">32886179</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23968886">
<a name="23968886"></a>Worthington I, Pringsheim T, Gawel MJ, et al; Canadian Headache Society Acute Migraine Treatment Guideline Development Group. Canadian Headache Society Guideline: acute drug therapy for migraine headache. <i>Can J Neurol Sci</i>. 2013;40(5 suppl 3):S1-S80.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naratriptan-drug-information/abstract-text/23968886/pubmed" id="23968886" target="_blank">23968886</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30240072">
<a name="30240072"></a>Yusuf A, Chia V, Xue F, Mikol DD, Bollinger L, Cangialose C. Use of existing electronic health care databases to evaluate medication safety in pregnancy: triptan exposure in pregnancy as a case study. <i>Pharmacoepidemiol Drug Saf</i>. 2018;27(12):1309-1315. doi:10.1002/pds.4658<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naratriptan-drug-information/abstract-text/30240072/pubmed" id="30240072" target="_blank">30240072</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 10167 Version 235.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
